NCT06909253

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Detailed description

The Polish, prospective, multicenter, observational, cohort study designed to collect longitudinal data on the management and clinical outcomes of patients with gMG naive to complement inhibitors who received ravulizumab in the scope of routine clinical practice within the frames of National Drug Program (NDP) for up to 42 months (\~ 6 months baseline and \~36 months follow-up).

Conditions

• Myasthenia Gravis, Generalized

Interventions

Type	Name	Description
DRUG	Ravulizumab	Ravulizumab, concentrate for solution for infusion

Timeline

• Start date: 2025-05-15
• Primary completion: 2029-12-31
• Completion: 2029-12-31
• First posted: 2025-04-03
• Last updated: 2026-04-17

Locations

14 sites across 1 country: Poland

Regulatory

• FDA-regulated drug study